Clinical Trial Update: CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X) [Phase 2]

View source ↗

Summary

A Phase 2 trial (CAPE-X) evaluating CAPEcitabine as adjuvant therapy for pancreatic cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Capecitabine (capecitabine)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Pancreas Cancer, Pancreas Adenocarcinoma | Phase 2 | Status: WITHDRAWN